SAN DIEGO--(BUSINESS WIRE)--Metabasis Therapeutics, Inc. (Nasdaq:MBRX), a biopharmaceutical company focused on the discovery, development and commercialization of novel drugs for the treatment of metabolic and liver diseases by applying unique capabilities for targeting the liver and liver pathways, announced today that two posters were presented at the Endocrine Society’s 89th Annual Meeting in Toronto, Canada.
